Page 10 - Flipbook
P. 10
Prostate Cancer Clinical Course
• Heterogenous disease ranging from indolent to life-threatening
Tumour Burden (PSA level)
Time (years)
Nonmetastatic
Castration-Resistant
Clinically Localized Nonmetastatic Metastatic
Primary Disease Castration-Sensitive Castration-Resistant Bone Metastases
Metastatic
Castration-Sensitive
De novo Metastatic Castration-Sensitive
PSA, prostate-specific antigen.
10
Adapted from Abou D et al. Front Oncol. 2020 Jun 5;10:554. doi:10.3389/fonc.2020.00884.
